Bio-Rad Laboratories (BIO) Non-Current Deffered Revenue (2015 - 2016)
Bio-Rad Laboratories' (BIO) quarterly Non-Current Deffered Revenue came in at $4.4 million in Q3 2016, up 17.55% on a QoQ basis from $3.7 million in Q4 2015.
Bio-Rad Laboratories (BIO) Non-Current Deffered Revenue (2015 - 2016) Analysis & Trends
Bio-Rad Laboratories (BIO) has 2 years of Non-Current Deffered Revenue data on file, last reported at $4.4 million in Q3 2016.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $4.4 million in Q3 2016; TTM through Sep 2016 was $4.4 million, a N/A change from a year earlier, with the FY2015 full-year figure at $3.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q3 2016 stood at $4.4 million, up from $3.7 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for BIO reached as high as $4.4 million in Q3 2016 and fell as low as $3.7 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 512.79 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Bio-Rad Laboratories | 8.53 Bn | 6.97 Bn | 309.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 4.40 Mn |
| Dec 31, 2015 | 3.74 Mn |